Skip to main content

NeoCOL

Delineating the risk factors and source of neonatal acquisition of multidrug-resistant gram-negative bacteria in high-burden countries in Southeast Asia and the Pacific.

The NeoCOL study is jointly funded by the National Health and Medical Research Council, The Sydney Infectious Diseases Institute, and the Avant Early Career research grant. This study aims to evaluate the timing and acquisition of multidrug-resistant bacterial colonisation for mothers and babies, and how this predisposes to the risk of infection. NeoCOL launched at Cipto Mangukusomo Hospital in Jakarta, Indonesia, in March 2024 with future sites across Southeast Asia planned in the near future. This study also aims to explore the impact of antibiotic exposure and colonisation with MDR bacteria on the infant microbiome, whilst a substudy is also exploring the prevalence of Group B Streptococcus (GBS) colonisation in Mothers, and the risk of subsequent GBS infection in babies.

Why is NeoCOL needed?

Neonatal colonisation with multidrug-resistant bacteria typically occurs before an episode of sepsis. This bacteria may be acquired vertically – ie, from the birth canal – or horizontally, due to exposure to bacteria in the hospital setting in the first days of life. 

There are limited data available globally to identify the chains of transmission between the community, mothers and babies predisposing to bacterial colonisation and infection. This study will help us better understand these pathways of infection and colonisation, to interrupt chains of transmission via optimal infection, prevention and control strategies.

What is involved in the study?

This study is systematically recruiting all eligible mother-infant-dyads birthing at Cipto Mangunkusumo Hospital in Jakarta, Indonesia. Swabs are taken from both the mother and infant at birth, and again from the infant at different time-points during their hospital admission, and once again at discharge. All participants will have detailed clinical and microbiological data collected and will each be followed up for six-months to understand the clinical outcomes associated with colonisation with multidrug-resistant bacteria. Environmental samples will also be collected to identify any sources that may be driving further transmission in the hospital environment.

Standard operating procedures:

  • Standard operating procedure 1: Neonatal Rectal Swab
    Download
  • Standard operating procedure 2: Maternal RectoVaginal Swab
    Download
  • Standard operating procedure 3: Stool Collection
    Download
  • Standard operating procedure 4: Genetic Sample Processing and Storage
    Download
  • Standard operating procedure 5: MDR Sample Processing and Storage
    Download
  • Standard operating procedure 6: GBS Swab Processing
    Download
  • Standard operating procedure 7: GBS positive isolate storage
    Download
  • Standard operating procedure 8: Environmental Swab collection and processing
    Download

Further Reading: